The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.

wikigene or wiki gene protein drug chemical gene disease author authorship tracking collaborative publishing evolutionary knowledge reputation system wiki2.0 global collaboration genes proteins drugs chemicals diseases compound
Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)
 
Chemical Compound Review

NSC-82344     oxo-dipropan-2-yloxy- phosphanium

Synonyms: AC1O3FKK, NSC82344, ZINC02577585, LS-106576, NSC 82344, ...
 
 
Welcome! If you are familiar with the subject of this article, you can contribute to this open access knowledge base by deleting incorrect information, restructuring or completely rewriting any text. Read more.
 

Disease relevance of DFP

  • Afferent granuloma cells produced a plasminogen-dependent, DFP inhibitable protease activity that was dependent on the cell concentration and the incubation time [1].
  • When soman or DFP was administered subcutaneously in high doses a severe AChE inhibition was obtained in iris without any concomitant miosis [2].
  • Motor incoordination (rotarod test) produced by DFP exposure had a rapid onset, with complete recovery by 10 hr [3].
  • Further administration of DFP (0.5 mg/kg/day, sc) for 6-14 days led to tolerance development as evidenced by disappearance of the described toxicity signs [4].
  • Further administration of DFP (14 days) caused disappearance of fasciculations and loss of sensitivity to the necrotizing actions in all muscles tested (diaphragm, soleus, and extensor digitorum longus) [5].
 

Psychiatry related information on DFP

 

High impact information on DFP

  • Enzymatic activity of cathepsin G is associated with its monocyte chemotactic activity, since DFP- or PMSF-inactivated cathepsin G no longer induced monocyte migration [8].
  • Recovery of PA activity from neutrophils was critically dependent on pretreatment of the intact cells with DFP before cavitation; 100-fold more PA activity was detected in DFP-pretreated cells [9].
  • Serine proteases or esterases released from cell cultures into the growth medium were converted to radioactive derivatives by active site labeling with tritiated DFP, both in the presence and absence of other competing active site reagents [10].
  • Other ligands (free uPA, ATF and DFP-treated uPA) were not internalized nor degraded [11].
  • Compared with control subjects, both diabetic and nondiabetic twins showed greater LPS-induced downregulation of monocyte COX-1 mRNA (P = 0.02), reduced upregulation of COX-2 mRNA and protein (P < 0.03), and greater inhibition by the COX-2 inhibitor di-isopropylfluorophosphate (DFP) of monocyte PGE(2) (P < 0.007) [12].
 

Chemical compound and disease context of DFP

 

Biological context of DFP

  • Poorly or non-phosphorylating analogues of the cyclohexyl alkylphosphonofluoridates of DFP were not inhibitory; nor did fluoride, the hydrolysis product of these inhibitors, inhibit ingestion under either condition [17].
  • Both the enzymatic and hemolytic activity of D were irreversibly inhibited by treatment with 10 mM DFP as well as by reduction and alkylation [18].
  • In contrast to tissue thromboplastin produced by other M phi populations, the H-M phi PCA was found to be markedly sensitive both to heat inactivation at 56 degrees C and to inhibition by 1 mM DFP [19].
  • The inhibitors of methyltransferase, SIBA, adenosine, or HEH showed a dose-dependent inhibitory effect not only on phospholipid methylation but also on serine esterase activation and on BCDF-induced IgG production; DFP inhibited IgG production but not phospholipid methylation [20].
  • In synchronized cells, signals provided by TRF could be transduced only when cells were in the G1-phase, and DFP showed an inhibitory effect only when it was added to cells in the G1-phase with TRF [21].
 

Anatomical context of DFP

  • All three antibodies partially inhibited the binding of EAC14o23b to tonsil lymphocytes and, in the presence of 0.1 mM DFP, to Raji cells; binding of EAC14o23bi and EAC14o23d to tonsil cells was not affected [22].
  • In order to isolate the DFP binding peptide, liver microsomes were labeled with [3H]DFP and the 60-kDa protein containing covalently bound DFP isolated in pure form [23].
  • Expression of the mutagenized cDNAs in COS-1 cells demonstrated that any single substitution of Gly629, Ser631, or Gly633 with other residues resulted in the complete loss of the enzyme activity and DFP binding [24].
  • The alteration in NF subunit protein levels observed in DFP-treated hen spinal cords was not observed in protected hens [25].
  • In 36-day-old chicks, PMSF (300 mg/kg) promoted OPIDP when given up to 5 days after DFP (1.5 mg/kg) when residual NTE inhibition in brain and sciatic nerve was about 40% [26].
 

Associations of DFP with other chemical compounds

 

Gene context of DFP

  • 4. No changes in any CSF release or HT-29 cell apoptosis were detected in the presence of the COX-2 selective inhibitor DFP (10(-7)-10(-4) M) [31].
  • The enzyme activity was inhibited by serine-protease inhibitors, such as DFP and PMSF, indicating that the KEX2 endopeptidase belongs to a serine-protease family [32].
  • Hence the DFP induced astroglial pathology as indicated by the complex expression profile of GFAP and vimentin mRNA levels may be playing an important role in the delayed degeneration of axons or is the result of progressive degeneration of axons in OPIDN [33].
  • At 1 1/2 and 24 hr after the DFP treatments, BuChE was considerably more depressed than was the case for AChE [34].
  • Plasma from indomethacin- or DFP-, but not from SC-560-treated rats abolished cyclooxygenase-2 activity in activated A549 cells [35].
 

Analytical, diagnostic and therapeutic context of DFP

  • Following reduction and carboxymethylation, the DFP-labeled protein was fragmented with trypsin and the digest subjected to gel filtration [23].
  • Two young adult cats were given a single, intraperitoneal injection of di-isopropylfluorophosphate (DFP) [36].
  • Young adult cats were given a single intraperitoneal injection of di-isopropylfluorophosphate (DFP) and were killed 14, 18, 20, 21, and 28 days later by intracardiac perfusion with aldehydes [37].
  • The Flinders Sensitive Line (FSL) rat, selectively bred for increased responses to the anticholinesterase DFP, was originally proposed as an animal model of depression because, like depressed humans, it is supersensitive to the behavioral and hormonal effects of cholinergic (muscarinic) agonists [38].
  • The results indicate that effective prosthetic orifice area may be computed by the pressure independent equation A = 21SV/DFP2, where A is the effective prosthesis orifice area in cm2, SV is the stroke volume in ml and DFP is the diastolic filling period in s min-1 [39].

References

  1. The production of plasminogen activator by afferent but not efferent lymph cells emigrating from chronic granulomatous lesions in sheep. Wasi, S., Vadas, P., Chin, G.W., Movat, H.Z., Hay, J.B. J. Immunol. (1982) [Pubmed]
  2. Correlations between acetylcholinesterase activity in guinea-pig iris and pupillary function: a biochemical and pupillographic study. Søli, N.E., Karlsen, R.L., Opsahl, M., Fonnum, F. J. Neurochem. (1980) [Pubmed]
  3. Relationship between the pharmacological effects and the biodisposition of [3H]diisopropylfluorophosphate in mice after inhalation. Scimeca, J.A., Little, P.J., Martin, B.R. Toxicol. Appl. Pharmacol. (1985) [Pubmed]
  4. Interaction of cycloheximide and diisopropylphosphorofluoridate (DFP) during subchronic administration in rat. Gupta, R.C., Dettbarn, W.D. Toxicol. Appl. Pharmacol. (1987) [Pubmed]
  5. Mechanisms of toxicity and tolerance to diisopropylphosphorofluoridate at the neuromuscular junction of the rat. Gupta, R.C., Patterson, G.T., Dettbarn, W.D. Toxicol. Appl. Pharmacol. (1986) [Pubmed]
  6. Di-isopropyl phosphofluoridate-induced antinociception: possible role of endogenous opioids. Koehn, G.L., Henderson, G., Karczmar, A.G. Eur. J. Pharmacol. (1980) [Pubmed]
  7. Prevention of morphine-induced muscarinic (M2) receptor adaptation suppresses the expression of withdrawal symptoms. Zhang, L.C., Buccafusco, J.J. Brain Res. (1998) [Pubmed]
  8. Identification of human neutrophil-derived cathepsin G and azurocidin/CAP37 as chemoattractants for mononuclear cells and neutrophils. Chertov, O., Ueda, H., Xu, L.L., Tani, K., Murphy, W.J., Wang, J.M., Howard, O.M., Sayers, T.J., Oppenheim, J.J. J. Exp. Med. (1997) [Pubmed]
  9. Human neutrophil plasminogen activator is localized in specific granules and is translocated to the cell surface by exocytosis. Heiple, J.M., Ossowski, L. J. Exp. Med. (1986) [Pubmed]
  10. Serine enzymes released by cultured neoplastic cells. Danø, K., Reich, E. J. Exp. Med. (1978) [Pubmed]
  11. Receptor-mediated internalization and degradation of urokinase is caused by its specific inhibitor PAI-1. Cubellis, M.V., Wun, T.C., Blasi, F. EMBO J. (1990) [Pubmed]
  12. Altered monocyte cyclooxygenase response to lipopolysaccharide in type 1 diabetes. Beyan, H., Goodier, M.R., Nawroly, N.S., Hawa, M.I., Bustin, S.A., Ogunkolade, W.B., Londei, M., Yousaf, N., Leslie, R.D. Diabetes (2006) [Pubmed]
  13. Role of uptake of [14C]valine into protein in the development of tolerance to diisopropylphosphorofluoridate (DFP) toxicity. Gupta, R.C., Dettbarn, W.D. Toxicol. Appl. Pharmacol. (1986) [Pubmed]
  14. Promotion of organophosphate-induced delayed polyneuropathy by phenylmethanesulfonyl fluoride. Lotti, M., Caroldi, S., Capodicasa, E., Moretto, A. Toxicol. Appl. Pharmacol. (1991) [Pubmed]
  15. Interactions between anticholinesterase poisoning and opioid analgesia and locomotion in mice. Green, P.G., Kitchen, I., Crowder, M. Neurotoxicology and teratology. (1988) [Pubmed]
  16. Types of adrenocorticoids and their effect on organophosphorus-induced delayed neuropathy in chickens. Ehrich, M., Jortner, B.S., Gross, W.B. Toxicol. Appl. Pharmacol. (1988) [Pubmed]
  17. The role of an activatable esterase in immune-dependent phagocytosis by human neutrophils. Musson, R.A., Becker, E.L. J. Immunol. (1977) [Pubmed]
  18. Human factor D of the alternative complement pathway: purification and characterization. Volanakis, J.E., Schrohenloher, R.E., Stroud, R.M. J. Immunol. (1977) [Pubmed]
  19. The induction of a unique procoagulant activity in rabbit hepatic macrophages by bacterial lipopolysaccharides. Maier, R.V., Ulevitch, R.J. J. Immunol. (1981) [Pubmed]
  20. Sequential induction of phospholipid methylation and serine esterase activation in a B cell differentiation factor (BCDF)-stimulated human B cell line. Kishi, H., Miki, Y., Kikutani, H., Yamamura, Y., Kishimoto, T. J. Immunol. (1983) [Pubmed]
  21. The requirement for esterase activation in T cell replacing factor (TRF)-induced IgG production in a human B blastoid cell line. Miki, Y., Kishi, H., Muraguchi, A., Kishimoto, S., Yamamura, Y., Kishimoto, T. J. Immunol. (1982) [Pubmed]
  22. Use of monoclonal antibodies against factor H to investigate the role of a membrane-associated protein antigenically related to H in C3b-receptor function. Schulz, T.F., Scheiner, O., Alsenz, J., Lambris, J.D., Dierich, M.P. J. Immunol. (1984) [Pubmed]
  23. Isolation and characterization of a 60-kilodalton glycoprotein esterase from liver microsomal membranes. Ozols, J. J. Biol. Chem. (1987) [Pubmed]
  24. Identification of the active site residues in dipeptidyl peptidase IV by affinity labeling and site-directed mutagenesis. Ogata, S., Misumi, Y., Tsuji, E., Takami, N., Oda, K., Ikehara, Y. Biochemistry (1992) [Pubmed]
  25. Protein levels of neurofilament subunits in the hen central nervous system following prevention and potentiation of diisopropyl phosphorofluoridate (DFP)-induced delayed neurotoxicity(1). Xie, K., Gupta, R.P., Abou-Donia, M.B. Biochem. Pharmacol. (2002) [Pubmed]
  26. Organophosphate polyneuropathy in chicks. Peraica, M., Capodicasa, E., Moretto, A., Lotti, M. Biochem. Pharmacol. (1993) [Pubmed]
  27. Isolation of an active-site peptide of lipoprotein lipase from bovine milk and determination of its amino acid sequence. Reddy, M.N., Maraganore, J.M., Meredith, S.C., Heinrikson, R.L., Kézdy, F.J. J. Biol. Chem. (1986) [Pubmed]
  28. Natural release of covalently bound C3b from cell surfaces and the study of this phenomenon in the fluid-phase system. Venkatesh, Y.P., Minich, T.M., Law, S.K., Levine, R.P. J. Immunol. (1984) [Pubmed]
  29. Binding of human urokinase-type plasminogen activator to its receptor: residues involved in species specificity and binding. Quax, P.H., Grimbergen, J.M., Lansink, M., Bakker, A.H., Blatter, M.C., Belin, D., van Hinsbergh, V.W., Verheijen, J.H. Arterioscler. Thromb. Vasc. Biol. (1998) [Pubmed]
  30. The mipafox-inhibited catalytic domain of human neuropathy target esterase ages by reversible proton loss. Kropp, T.J., Glynn, P., Richardson, R.J. Biochemistry (2004) [Pubmed]
  31. Relationship between endogenous colony stimulating factors and apoptosis in human colon cancer cells: role of cyclo-oxygenase inhibitors. Calatayud, S., Warner, T.D., Breese, E.J., Mitchell, J.A. Br. J. Pharmacol. (2001) [Pubmed]
  32. Characterization of KEX2-encoded endopeptidase from yeast Saccharomyces cerevisiae. Mizuno, K., Nakamura, T., Ohshima, T., Tanaka, S., Matsuo, H. Biochem. Biophys. Res. Commun. (1989) [Pubmed]
  33. Alterations in levels of mRNAs coding for glial fibrillary acidic protein (GFAP) and vimentin genes in the central nervous system of hens treated with diisopropyl phosphorofluoridate (DFP). Damodaran, T.V., Abou-Donia, M.B. Neurochem. Res. (2000) [Pubmed]
  34. Changes in the levels and forms of rat plasma cholinesterases during chronic diisopropylphosphorofluoridate intoxication. Traina, M.E., Serpietri, L.A. Biochem. Pharmacol. (1984) [Pubmed]
  35. Effects of cyclooxygenase-1/cyclooxygenase-2 inhibition on leukocyte/endothelial cell interactions in the rat mesentery. Calatayud, S., Mitchell, J.A., Perretti, M., Giuliano, F., Warner, T.D. Eur. J. Pharmacol. (2002) [Pubmed]
  36. Organophosphorous neuropathy. II. A fine-structural study of the early stages of axonal degeneration. Bouldin, T.W., Cavanagh, J.B. Am. J. Pathol. (1979) [Pubmed]
  37. Organophosphorous neuropathy. I. A teased-fiber study of the spatio-temporal spread of axonal degeneraion. Bouldin, T.W., Cavanagh, J.B. Am. J. Pathol. (1979) [Pubmed]
  38. The Flinders sensitive line rats: a genetic animal model of depression. Overstreet, D.H. Neuroscience and biobehavioral reviews. (1993) [Pubmed]
  39. An orifice formula independent of mitral pressure gradient for the evaluation of prosthetic mitral valve obstruction. Seitz, W.S., Hosenpud, J.D., Schutz, R. Eur. Heart J. (1984) [Pubmed]
 
WikiGenes - Universities